Screener
Maze Therapeutics MAZE PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Marketable securities, current | 208,444 | 152,670 |
| Prepaid expenses and other current assets | 9,336 | 7,800 |
| Total current assets | 420,423 | 349,717 |
| Property and equipment, net | 4,391 | 5,044 |
| Restricted cash | 1,088 | 1,088 |
| Marketable securities, non-current | 83,821 | 18,114 |
| Operating lease right-of-use asset | 18,442 | 20,116 |
| Other assets | 3,460 | 3,048 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's PP&E (net)?
- Maze Therapeutics (MAZE) reported PP&E (net) of $4.39M in Q2 2026.
- How has Maze Therapeutics's PP&E (net) changed year-over-year?
- Maze Therapeutics's PP&E (net) decreased by 26.9% year-over-year, from $6.01M to $4.39M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Maze Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude